$CYCU

Cycurion Inc. (CYCU) announced an agreement to acquire Kustom Entertainment's video solutions unit, including Digital Ally-branded systems and 58 patents. The deal, valued at up to $6.5 million, is expected to close in early July 2026. CYCU stock rose over 2% on the news, despite a 77% year-to-date decline. The acquisition aims to combine Kustom's video capabilities with Cycurion's cybersecurity platform, expanding its customer base and recurring revenue.

Cycurion, Inc. (CYCU) was upgraded to a Zacks Rank #2 (Buy) due to upward trends in earnings estimates. The Zacks Consensus Estimate for CYCU has increased 76.9% over the past three months, suggesting a positive outlook for the company's earnings. This upgrade places CYCU in the top 20% of Zacks-covered stocks, potentially indicating near-term stock price appreciation.

Cycurion (CYCU) announced new contracts worth about $800,000 annually, including engagements in healthcare, life sciences, and public health. The awards support its strategy to expand into commercial sectors beyond government work, with projects in cybersecurity, program management, and organizational change.

Cycurion reported ~$800,000 in annual contract spend from new clients, including a pharma AI CoE and NACCHO, expanding into commercial healthcare and life sciences.

Cycurion (CYCU) shares rose 15% after announcing a $1M strategic partnership with a Fortune 500 company. The multi-year deal covers AI, security, and support. CYCU stock breached its 50-DMA for the first time since November 2025. The company expects growth and expansion opportunities.

Cycurion, Inc. (NASDAQ: CYCU) reported a $30 million annual revenue run rate, a 29.1% gross margin, and a $54.6 million 10-year contract. The company also announced a $500,000 share repurchase plan and reduced net debt by over half since 2024. Cycurion has 3.2 million outstanding shares and expects $15-$17 million in committed revenue annually through 2028.

Cycurion Inc. (CYCU) shares rose 37% in premarket trading after securing a $54.6M, 10-year contract for health IT modernization, adding to a 496% gain the prior day. The deal is expected to generate over $5M in annual revenue starting November 2026. The company reported a narrowed net loss and improved gross margins in Q1 2026. Analysts maintain a Buy rating with a $7.00 price target. Cycurion also faces a Nasdaq delisting threat for failing to meet the minimum bid price requirement, with a hear

Cycurion (CYCU) completed a 1-for-8 reverse stock split, reducing shares from 25.8M to 3.23M, effective August 28, 2026. The move aims to meet Nasdaq's minimum bid price requirements, with trading continuing under the same ticker.

Cycurion (NASDAQ: CYCU) announced a 1-for-8 reverse stock split to meet NASDAQ requirements. The company reported a gross margin increase to 29.1% and a $54.6M 10-year HHS contract. It also authorized a $500K share repurchase program and aims for profitability by Q2 2027. CEO Kevin Kelly addressed market manipulation allegations.

Cycurion (CYCU) announced a 1-for-8 reverse stock split and a 10-year, $54.6M deal with HHS, expected to generate over $5M in annual recurring revenue. The company reported improved gross margins (29.1% in Q2 2026 vs. 6.1% in Q2 2025) and reduced net debt. Management targets profitability by Q2 2027 and authorized a $500K share repurchase program.